Paul Wagner - Forte Biosciences President CEO
| FBRX Stock | USD 7.54 0.52 7.41% |
CEO
Paul Wagner is President CEO of Forte Biosciences
| Age | 55 |
| Address | 3060 Pegasus Park Drive, Dallas, TX, United States, 75247 |
| Phone | 310 618 6994 |
| Web | https://www.fortebiorx.com |
Paul Wagner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Wagner against Forte Biosciences stock is an integral part of due diligence when investing in Forte Biosciences. Paul Wagner insider activity provides valuable insight into whether Forte Biosciences is net buyers or sellers over its current business cycle. Note, Forte Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Forte Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Wagner few days ago Acquisition by Paul Wagner of 31250 shares of Forte Biosciences subject to Rule 16b-3 | ||
Paul Wagner over two months ago Disposition of 1250 shares by Paul Wagner of Forte Biosciences subject to Rule 16b-3 | ||
Paul Wagner over three months ago Disposition of 11046 shares by Paul Wagner of Forte Biosciences at 1.01 subject to Rule 16b-3 | ||
Paul Wagner over three months ago Disposition of 1250 shares by Paul Wagner of Forte Biosciences subject to Rule 16b-3 |
Forte Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.6766) % which means that it has lost $0.6766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.374) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2025. Return On Capital Employed is likely to drop to -0.87 in 2025. At this time, Forte Biosciences' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 831.9 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 558.3 K in 2025.Similar Executives
| Found 6 records | CEO Age | ||
| Jeffrey JD | Indaptus Therapeutics | 58 | |
| Kevin Koch | Edgewise Therapeutics | 65 | |
| Nevan JD | Rezolute | 58 | |
| Andrew MBA | C4 Therapeutics | 54 | |
| Tiago MD | Pasithea Therapeutics Corp | 48 | |
| LLM JD | Tempest Therapeutics | 55 | |
Management Performance
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.68 |
Forte Biosciences Leadership Team
Elected by the shareholders, the Forte Biosciences' board of directors comprises two types of representatives: Forte Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Forte. The board's role is to monitor Forte Biosciences' management team and ensure that shareholders' interests are well served. Forte Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Forte Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antony CPA, Chief Officer | ||
| Steven Ruhl, Chief Officer | ||
| Paul Wagner, President CEO | ||
| Hubert MD, President Officer | ||
| Christopher Roenfeldt, Chief Officer | ||
| Barbara MD, Chief Director |
Forte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Forte Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 28.52 M | ||||
| Shares Outstanding | 6.39 M | ||||
| Shares Owned By Insiders | 9.71 % | ||||
| Shares Owned By Institutions | 80.06 % | ||||
| Number Of Shares Shorted | 28.28 K | ||||
| Price To Book | 4.79 X | ||||
| EBITDA | (32.48 M) | ||||
| Net Income | (31.48 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.